Loading stock data…
BLTE
$154.85-4.31 (-2.71%)
Market ClosedLast close May 1
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Belite Bio, Inc in the Healthcare sector is trading at $154.85. The stock is currently 23% below its 52-week high of $200.00, remaining 23.7% above its 200-day moving average. Technical signals show neutral RSI of 32 and bearish MACD signal, explaining why BLTE maintains its current momentum and trend strength. The Whystock Score of 95/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Oversold momentum (RSI 32) — potential for technical mean-reversion
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$154.85
Potential Upside
5%
Whystock Fair Value$162.59
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus8 analysts
Mean target$211.50+36.6%
Range$185.00 – $266.00
Fundamentals
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. Its lead product ca...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$6.69B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-1.22
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-1.09%
Volume
Today's trading volume
77,246
Recent News
Belite Bio (BLTE) Initiates Rolling NDA Submission to FDA for Tinlarebant in STGD1
Belite Bio (NASDAQ:BLTE) is one of the best up and coming stocks with highest upside potential. On April 21, Belite Bio begun a rolling submission of an NDA to the FDA for tinlarebant, a potential first-ever treatment for Stargardt disease type 1/STGD1. This rare, progressive genetic disorder leads to legal blindness and currently has no […]
Belite Bio Shares Tinlarebant Phase III Stargardt Data, FDA Rolling Submission at DB Conference
Belite Bio (NASDAQ:BLTE) highlighted progress for its lead drug candidate tinlarebant during the 30th Deutsche Bank Depositary Receipts Virtual Investor Conference, outlining late-stage clinical development in Stargardt disease and geographic atrophy (GA) and describing Phase III efficacy and safety
How Belite Bio’s (BLTE) Rolling FDA NDA For Tinlarebant Has Changed Its Investment Story
Belite Bio has recently begun a rolling New Drug Application submission to the U.S. FDA for tinlarebant, an oral therapy targeting Stargardt disease type 1, supported by Breakthrough Therapy, Fast Track, Orphan Drug, Rare Pediatric Disease, and Sakigake designations across major regions. This step could position tinlarebant as a first-in-class treatment for a rare inherited retinal disorder, while also underpinning Belite Bio’s broader development in geographic atrophy through ongoing Phase...
When Can We Expect A Profit From Belite Bio, Inc (NASDAQ:BLTE)?
We feel now is a pretty good time to analyse Belite Bio, Inc's ( NASDAQ:BLTE ) business as it appears the company may...
Belite Bio Details Phase 3 DRAGON Win as Tinlarebant Cuts Stargardt Lesion Growth 36% at Conference
Belite Bio (NASDAQ:BLTE) Chief Medical Officer Hendrik Scholl outlined the company’s approach to treating Stargardt disease and reviewed top-line results from its Phase 3 DRAGON trial during a conference session hosted by Leerink analyst Marc Goodman. Stargardt disease: prevalence and unmet need Sc